Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LSS | P48449 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15125623 | 0.94 | HRH3 (0.71) | HRH3KCNH2CYP2C19CYP1A2TSHR | |
| SCHEMBL11320124 | 0.88 | HRH3 (0.61) | HRH3KCNH2CYP2C19CYP1A2TSHR | |
| SCHEMBL1728531 | 0.86 | HRH3 (0.58) | HRH3KCNH2CYP2C19CYP1A2TSHR | |
| SCHEMBL15706263 | 0.82 | KCNH2 (0.48) | KCNH2CYP2C19CYP1A2TSHRLMNA | |
| SCHEMBL659509 | 0.82 | HRH3 (0.82) | HRH3TSHRALDH1A1TAAR1ACHE | |
| SCHEMBL12891088 | 0.80 | KCNH2 (0.53) | HRH3KCNH2CYP2C19CYP1A2TSHR | |
| SCHEMBL10178754 | 0.80 | HRH3 (0.52) | HRH3KCNH2CYP2C19CYP1A2TSHR | |
| SCHEMBL10783875 | 0.79 | LMNA (0.46) | KCNH2TSHRLMNAACHEADRA2A | |
| SCHEMBL13941980 | 0.79 | KCNH2 (0.46) | KCNH2CYP2C19CYP1A2TSHRLMNA | |
| SCHEMBL10261974 | 0.79 | LSS (0.63) | HRH3TSHRALDH1A1TAAR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-20230065217-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3697758-B1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| EP-3356426-B1 | A PROCESS FOR PREPARING FUNCTIONAL POLYMERS THROUGH ADDITION OF AMINO AND POLYMERYL GROUPS TO ALDEHYDE MOIETIES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-19 | — | — | US | disclosed |
| US-20080306062-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008064311-A2 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| WO-2008054718-A2 | COMPOUNDS AND COMPOSITIONS CONTAINING SILICON AND/OR OTHER HETEROATOMS AND/OR METALS AND METHODS OF MAKING AND USING THEM | WAKE FOREST UNIVERSITY (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-7196090-B2 | Kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-7176231-B2 | Aryl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065217-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | HRH3 363/4885KCNH2 871/4885CYP2C19 3305/4885 |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | HRH3 118/4885KCNH2 2493/4885CYP2C19 1162/4885 |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, CRH | HRH3 85/4885KCNH2 2623/4885CYP2C19 409/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | HRH3 2113/4885KCNH2 1283/4885CYP2C19 436/4885 |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | HRH3 2248/4885KCNH2 3053/4885CYP2C19 2080/4885 |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | HRH3 380/4885KCNH2 3504/4885CYP2C19 1577/4885 |
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | HRH3 3573/4885KCNH2 1146/4885CYP2C19 1649/4885 |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | HRH3 3573/4885KCNH2 1146/4885CYP2C19 1649/4885 |
| US-20080306062-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | HRH3 3573/4885KCNH2 1146/4885CYP2C19 1649/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | HRH3 2884/4885KCNH2 4656/4885CYP2C19 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.